Medicines for Malaria Venture (MMV)

“If we wait for the next resistance crisis, it’ll be too late.” The history of #malaria drug resistance is a warning: innovation must stay ahead of the parasite. MMV's Martin Fitchet and ALMA's Joy Phumaphi discuss what's at stake with @devex.com. Watch more: bit.ly/4igZlHs

For the 5th straight year, MMV is a “Very high performer” in the #GlobalHealth5050 Gender & Health Index! Gender equity drives better science, stronger partnerships and greater impact towards #malaria elimination. Check out the full report: bit.ly/4itEm5H

New treatment regimens for relapsing #malaria could simplify care and reduce onward transmission. Join tomorrow's webinar on single-dose tafenoquine to explore how countries can overcome implementation barriers and maximise its benefits. Register for free: bit.ly/4hX3ujQ

A #malaria infection during pregnancy can turn joyful anticipation into fear and uncertainty. A new @who.int knowledge portal aims to close critical evidence gaps by supporting the inclusion of pregnant and breastfeeding women in clinical trials. Learn more: bit.ly/3Wayd5E

One of TIME's Best Inventions of 2026! MMV and @deepmirror.bsky.social's AI-powered dd4gh platform is helping accelerate drug discovery for #malaria and neglected diseases while broadening access to advanced research tools for scientists in affected countries: bit.ly/4zu143h

From crisis to resilience. That was the ambition of #WHS2026. For us, the way forward means building on proven partnerships and expertise, with countries taking a greater lead in setting health priorities and developing new tools. Thanks to everyone who contributed to the discussions!

Global health is evolving, and so are we. Today, MMV and partners published a joint paper exploring how research, innovation and product development can help build a more sovereign, resilient and equitable future for health. Read the paper: bit.ly/4enkZsr

At @worldhealthsummit.bsky.social in Berlin, @dndi.org, @gardp.bsky.social & MMV invited partners to explore how stronger collaboration can sustain health innovation, strengthen local capabilities and accelerate access to the treatments people need. Turning shared ambition into collective action.

Global health has no shortage of ambition. Turning it into impact takes collaboration. At @worldhealthsummit.bsky.social, MMV and partners explored how the product development partnership model can help make global health innovation more effective and sustainable.

Where medicines are made impacts who can access them. Africa is heavily reliant on imports for the medicines needed to fight #malaria. MMV works with African manufacturers and Africa CDC to strengthen local production and bring medicines closer to patients. bit.ly/4zc2X4m

What can investments in global health make possible? Through the EDCTP, EU investments advance new health tools, build scientific capacity & attract additional funding, with every €1 mobilizing more than €1 from other sources. Read our paper: bit.ly/4xKn21U

When resources are under pressure, innovation becomes even more important. Drug and insecticide resistance, climate change and conflict threaten #malaria progress. New tools can keep us ahead of resistance, simplify care & make the most of limited resources bit.ly/4xCEkwB

There are places we expect #malaria transmission. Germany isn't one of them. Cases have appeared near Frankfurt Airport. As temps rise, transmission conditions are changing. A reminder that reducing malaria everywhere strengthens global health security. bit.ly/3VVJBSL

What keeps progress against #malaria moving? In Liverpool, @malarianomoreuk.bsky.social ambassador Gab Astorga put that question to malaria scientists & global health experts. See what they had to say

Following encouraging Phase 2a results, MMV will lead the next phase of cabamiquine's development. Long-acting cabamiquine, with potential to become a single-dose treatment or prevention option, could help address drug resistance & block transmission: bit.ly/4ypoy9x

PNG shoulders a disproportionate share of the Indo-Pacific's #malaria burden. Closing the gap means understanding why progress is harder in some settings vs others. In PNG, MMV met with partners & communities to explore the strategies and tools needed to accelerate elimination.

The Malaria Science Index shows how investment in #malaria R&D strengthens global health security and delivers #innovation beyond malaria. It also shows how UK science benefits from international collaboration. Sustained investment is key to elimination: bit.ly/47iA8HC

Each breakthrough in global health starts with a partnership. The UK is committing more than £100m to product development partnerships (PDPs). For #malaria, sustained investment in PDPs like MMV can help make the next breakthroughs possible. Read more: bit.ly/4he33kP

One dose to cure #malaria. That's the ambition behind WANECAM3, an Africa-Europe consortium developing new tools to change how we fight the disease. Prof. Abdoulaye Djimdé & his team in Mali are providing the scientific leadership to help make it happen: bit.ly/4cS0Dag

What will it take to end #malaria? New tools that can simplify care. Single-dose cures and long-acting prevention could become elimination accelerators, taking us closer to the finish line. Sustained investment can help get them there.

#ClimateChange is no longer simply a future threat, but a reality we need to manage and adapt to. For #malaria, building resilience is critical. This means developing simpler medicines that are easier to deliver and use, while strengthening health systems and supply chains.

#Malaria treatment and prevention needs vary by patient, context and setting. A new review explores how #innovation must respond, from simplifying treatment and providing longer-lasting protection to staying ahead of drug resistance. Read more: bit.ly/46m7KUO

Different patients need medicines designed for their particular needs. Coartem® Baby, the first antimalarial developed for newborns and young infants weighing 2–5 kg, is now included in the WHO Guidelines for #malaria, supporting broader access. Read more: bit.ly/4iqa5Fr

Does your organization have insights into how AI can improve clinical trial design and documentation? MMV, @dndi.org and @gardp.bsky.social are mapping AI solutions for clinical study design, operations and medical writing. Submission deadline: 7 October Learn more: bit.ly/3UMwkeW

Women should be protected through research, not from it. Healthcare decisions need evidence, but pregnant & breastfeeding women have historically been excluded from clinical research, leaving critical data gaps. Read our recommendations for ICH E21: bit.ly/3SKgP6C

#Malaria prevalence in Nigeria among children aged 6–59 months has declined by nearly 64% over the past 15 years. Sustained investment in prevention tools like SMC, treatment, surveillance and public awareness has helped drive this progress. Learn more: bit.ly/4qAN44B

MMV expresses profound sadness at the news of Vasee Moorthy’s untimely passing – we have lost an exceptional champion of global health. We will miss him sorely and send our deepest condolences to his myriad friends and his beloved family.

MMV has launched a request for information to identify organizations based in or operating in malaria-endemic countries for a new request for information on #malaria market intelligence and evidence generation. Deadline: 14 October Learn more: bit.ly/4cbgujY

The Africa–Europe WANECAM3 consortium has launched to advance next-generation #malaria treatments. Through Phase 2 & 3 trials, it aims to advance a single-dose cure to simplify treatment, improve adherence & address antimalarial drug resistance. Read more bit.ly/4x1j0kk

Scientists in Tanzania are seeing early warning signs of antimalarial drug resistance spreading geographically. Molecular surveillance helps countries track how resistance is evolving & make timely #malaria treatment decisions to stay ahead of the threat: bit.ly/4zJou5R

From discovery to delivery, collaboration underpins progress against #malaria. This summer in Tokyo, MMV, the GHIT Fund and @gatesfoundation.bsky.social brought together partners from Japan and around the world to strengthen connections and discuss the future of malaria R&D: bit.ly/3UcIUnz

Encouraging Phase 2 results are supporting further development of a potential new #malaria treatment and prevention combination, which makes use of a promising new compound co-discovered by @ddu-dundee.bsky.social and MMV. Learn more: bit.ly/4gpdanQ

Global health challenges require global collaboration. This #WorldMosquitoDay, as MMV's flag flies over Geneva, we're celebrating the city's role as a meeting point where partnerships connect expertise and #innovation with communities around the world. 🦟🌍

#WorldMosquitoDay reminds us that the fight against #malaria is an ongoing challenge, with resistance threatening the tools we rely on. Martin Fitchet & Michael Adekunle Charles call for investment in today's tools AND innovations to stay ahead of resistance bit.ly/4zsl6fc

Building bridges is what we do. For 25+ years, MMV has connected people, expertise and resources around the world. Different bridges, one destination: a #malaria-free future. A fitting spot for our #WorldMosquitoDay group shot!

#Malaria exploits disruption. A new @malariaconsortium.bsky.social study explores the challenges of delivering SMC in conflict- and flood-affected South Sudan, with lessons other complex settings can benefit from. Read more: bit.ly/4gsQByo

📢 Call for applications! @afro.who.int & TDR are supporting locally driven implementation research to strengthen health research capacity and generate evidence for countries. Applications: EN, FR & PT Deadline: 15 Sept 2026 Apply: bit.ly/4q9lV8A

What can a century of #malaria surveillance reveal about the impact of #ClimateChange in Africa? A study in @nature.com finds its impact on childhood malaria varies considerably across the continent, with new risks emerging in East & Southern Africa. More: bit.ly/4g0Yhyh

#Malaria prevention saves lives. It can also be an investment in children's education & future productivity. A new study suggests expanding SMC to school-aged children could deliver billions in health & economic benefits. More: bit.ly/4fDHBVu

Pregnant & breastfeeding women must be protected through clinical research, not from it. MMV & partners are calling for actionable guidance to support their inclusion in clinical research and generate robust evidence: bit.ly/4wLXBwa #WorldBreastfeedingWeek

Relapsing #malaria can cause repeated episodes of illness from a single mosquito bite. A new study from Papua New Guinea & Indonesia is helping build the evidence needed to introduce improved approaches into routine care. More: bit.ly/4fwLLOV

The cost of responding to antimalarial drug resistance in Africa will only grow as resistance spreads. Beyond new #malaria medicines, investment must also target surveillance, health systems and local manufacturing. More: bit.ly/4pP8Ilm

Congrats to MMV's André-Marie Tchouatieu, who was recognized for his visionary leadership in the fight against #malaria at Benin's La Nuit du Paludisme. The Exceptional Commitment Award celebrates his success in mobilizing minds, inspiring generations and saving countless lives.

Between 2019 and 2024, Ghana reduced #malaria deaths among children under 5 by 86%. Its experience shows the value of layering interventions and ensuring vaccines, bed nets, diagnosis, treatment and community-centred delivery work together. Read more: bit.ly/4fRxcH6

MMV met with leaders from the Japan Institute for Health Security (JIHS) to discuss Japan's approach to #malaria and health security, showcase MMV's pipeline of innovative malaria medicines and explore opportunities for future collaboration.

Long-acting injectables could provide protection from malaria for up to 6 months with a single administration. Cristina Donini explains how it works. Reaching zero #malaria requires continued #innovation & sustained commitment to get breakthroughs to those who need them most.

Spotlight on Japan: today, partners from around the world convened in Tokyo for the Japan symposium on #malaria R&D. Discussions focused on the partnerships, science & innovation advancing next-generation malaria prevention & treatment tools. More: bit.ly/4pucJLR

From discovery to delivery, collaboration across the global malaria community underpins innovation and progress. Here are three ways Japan contributes to the fight against one of the world's deadliest diseases.

#PressRelease A potential new antimalarial has shown promising results in its first study in humans. The investigational non-artemisinin medicine rapidly killed #malaria parasites and was generally well tolerated in infected volunteers. Read more: bit.ly/3T5KJ4Y

A single-dose cure for #malaria: one patient, one visit, one treatment, done. MMV’s Cristina Donini explains how it works. Reaching zero malaria requires continued #innovation and the sustained commitment to get the latest breakthroughs to the people who need them most.